ORIC-533 is under clinical development by ORIC Pharmaceuticals and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ORIC-533’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ORIC-533 overview
ORIC-533 is under development for the treatment of relapsed or refractory multiple myeloma. These are administered through oral route. The drug candidates act by targeting CD73.
See Also:
ORIC Pharmaceuticals overview
ORIC Pharmaceuticals is clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers. Its lead drug candidate ORIC-101, is a selective small molecule antagonist of the glucocorticoid receptor (GR), implicated in resistance to various treatment modalities such as chemotherapy, immunotherapy and anti-hormonal therapy across a broad range of cell lines and tumor types. The company is funded by EcoR1 Capital, The Column Group, OrbiMed Advisors, Topspin Partners, Foresite Capital and Kravis Investment Partners. ORIC Pharmaceuticals is headquartered in South San Francisco, California, the US.
For a complete picture of ORIC-533’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
